TABLE 2.
Pooled baseline characteristics of patients with type 2 diabetes in England, Germany, Japan, the Netherlands, Norway and Sweden
| All patients with T2D | CVRD‐free (reference group) | Cardiorenal disease | HF | CKD | Cardiorenal syndrome | Stroke | MI | PAD | |
|---|---|---|---|---|---|---|---|---|---|
| Number of patients | 1 177 896 | 772 336 | 60 466 | 17 626 | 42 840 | 8464 | 34 449 | 9376 | 11 633 |
| Age, years (SD) | 67.7 (12.7) | 65.2 (12.6) | 70.9 (12.2) | 73.2 (12.2) | 70.0 (11.9) | 74.7 (11.6) | 71.3 (10.8) | 70.0 (11.0) | 70.2 (10.5) |
| Women, n (%) | 507 305 (43.1) | 345 928 (44.8) | 28 417 (47.0) | 8907 (50.5) | 19 510 (45.5) | 4221 (49.9) | 14 084 (40.9) | 2681 (28.6) | 4290 (36.9) |
| CVD, n (%) | 318 578 (27.0) | 0 (0.0) | 60 466 (100.0) | 17 626 (100.0) | 42 840 (100.0) | 8464 (100.0) | 34 449 (100.0) | 9376 (100.0) | 11 633 (100.0) |
| Stroke, n (%) | 84 467 (7.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 34 449 (100.0) | 0 (0.0) | 0 (0.0) |
| Myocardial infarction, n (%) | 90 839 (7.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 9376 (100.0) | 0 (0.0) |
| UAP, n (%) | 45 699 (3.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| AP, n (%) | 148 903 (12.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| PAD, n (%) | 47 630 (4.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 11 633 (100.0) |
| Atrial fibrillation, n (%) | 85 828 (7.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Cardiorenal disease, n (%) | 1956 69 (16.6) | 0 (0.0) | 60 466 (100.0) | 17 626 (100.0) | 42 840 (100.0) | 8464 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| HF, n | 115 224 (9.8) | 0 (0.0) | 17 626 (29.2) | 17 626 (100.0) | 0 (0.0) | 8464 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| CKD, n | 120 597 (10.2) | 0 (0.0) | 42 840 (70.8) | 0 (0.0) | 42 840 (100.0) | 8464 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Cardiorenal syndrome, n (%) | 40 152 (3.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 8464 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Microvascular disease, n (%) | 216 342 (18.4) | 790 03 (10.2) | 24 642 (40.8) | 3996 (22.7) | 20 646 (48.2) | 4876 (57.6) | 8251 (24.0) | 2024 (21.6) | 4674 (40.2) |
| CVD prevention, n (%) | 918 896 (78.0) | 558 306 (72.3) | 49 703 (82.2) | 14 525 (82.4) | 35 178 (82.1) | 7394 (87.4) | 28 312 (82.2) | 8364 (89.2) | 10 096 (86.8) |
| Low‐dose aspirin, n (%) | 336 312 (28.6) | 141 815 (18.4) | 15 126 (25.0) | 4100 (23.3) | 11 026 (25.7) | 2134 (25.2) | 14 665 (42.6) | 5685 (60.6) | 5116 (44.0) |
| Statins, n (%) | 562 183 (47.7) | 322 219 (41.7) | 27 872 (46.1) | 6658 (37.8) | 21 214 (49.5) | 3563 (42.1) | 17 437 (50.6) | 6384 (68.1) | 6770 (58.2) |
| Anti‐hypertensives, n (%) | 772 986 (65.6) | 449 539 (58.2) | 44 807 (74.1) | 13 268 (75.3) | 31 539 (73.6) | 6780 (80.1) | 23 449 (68.1) | 7469 (79.7) | 8346 (71.7) |
| ACE, n (%) | 312 719 (26.5) | 160 777 (20.8) | 20 517 (33.9) | 6371 (36.1) | 14 146 (33.0) | 3027 (35.8) | 10 035 (29.1) | 3947 (42.1) | 4277 (36.8) |
| ARBs, n (%) | 329 812 (28.0) | 208 624 (27.0) | 20 214 (33.4) | 5448 (30.9) | 14 766 (34.5) | 3112 (36.8) | 9692 (28.1) | 2522 (26.9) | 3227 (27.7) |
| Beta blockers, n (%) | 379 213 (32.2) | 165 474 (21.4) | 19 373 (32.0) | 8103 (46.0) | 11 270 (26.3) | 4035 (47.7) | 9067 (26.3) | 5881 (62.7) | 3412 (29.3) |
| High ceiling diuretics, n (%) | 220 509 (18.7) | 73 498 (9.5) | 21 459 (35.5) | 9787 (55.5) | 11 672 (27.2) | 5815 (68.7) | 4895 (14.2) | 1892 (20.2) | 2080 (17.9) |
| Aldosterone antagonists, n (%) | 46 933 (4.0) | 13 639 (1.8) | 4197 (6.9) | 2891 (16.4) | 1306 (3.0) | 1191 (14.1) | 826 (2.4) | 412 (4.4) | 354 (3.0) |
| Metformin, n (%) | 647 512 (55.0) | 444 534 (57.6) | 25 634 (42.4) | 7647 (43.4) | 17 987 (42.0) | 2186 (25.8) | 17 480 (50.7) | 5550 (59.2) | 7063 (60.7) |
| Sulphonylureas, n (%) | 339 157 (28.8) | 218 948 (28.3) | 16 024 (26.5) | 4424 (25.1) | 11 600 (27.1) | 1677 (19.8) | 10 207 (29.6) | 2628 (28.0) | 3715 (31.9) |
| DPP‐4 inhibitors, n (%) | 265 896 (22.6) | 189 488 (24.5) | 14 206 (23.5) | 4631 (26.3) | 9575 (22.4) | 2346 (27.7) | 7341 (21.3) | 1836 (19.6) | 1807 (15.5) |
| SGLT2 inhibitors, n (%) | 13 732 (1.2) | 9908 (1.3) | 445 (0.7) | 157 (0.9) | 288 (0.7) | 53 (0.6) | 116 (0.3) | 77 (0.8) | 52 (0.4) |
| GLP‐1RAs, n (%) | 14 869 (1.3) | 10 859 (1.4) | 1122 (1.9) | 270 (1.5) | 852 (2.0) | 153 (1.8) | 246 (0.7) | 139 (1.5) | 125 (1.1) |
| Meglitinides, n (%) | 63 381 (5.4) | 30 574 (4.0) | 2924 (4.8) | 738 (4.2) | 2186 (5.1) | 469 (5.5) | 1262 (3.7) | 312 (3.3) | 394 (3.4) |
| Thiazolidinediones, n (%) | 50 547 (4.3) | 48 183 (6.2) | 3645 (6.0) | 553 (3.1) | 3092 (7.2) | 197 (2.3) | 1739 (5.0) | 379 (4.0) | 659 (5.7) |
| Acarbose, n (%) | 101 896 (8.7) | 58 521 (7.6) | 4210 (7.0) | 1145 (6.5) | 3065 (7.2) | 670 (7.9) | 1891 (5.5) | 486 (5.2) | 429 (3.7) |
| Insulin, n (%) | 366 462 (31.1) | 183 429 (23.7) | 22 057 (36.5) | 6052 (34.3) | 16 005 (37.4) | 3817 (45.1) | 10 266 (29.8) | 2853 (30.4) | 4068 (35.0) |
Abbreviations: ACE, angiotensin‐converting enzyme; UAP, unstable angina pectoris; AP, angina pectoris; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; CVD, cardiovascular disease; CVRD, cardiovascular or renal disease; DPP‐4, dipeptidyl‐peptidase‐4; GLP‐1RA, glucagon‐like peptide‐1 receptor agonist; HF, heart failure; MI, myocardial infarction; PAD, peripheral artery disease; SGLT2, sodium‐glucose co‐transporter‐2; UAP, xxx.